Parabilis Medicines

The team at Parabilis is the driving force – passionate, adaptable, and endlessly curious – that embodies our mission of making medicines that have extraordinary impact. On #EmployeeAppreciationDay, we want to take this opportunity to recognize each person on #TeamParabilis. Thank you for all that you do!?

We are proud to be at the cutting edge of innovation in drug discovery. Targeted protein degradation (TPD) shows great promise by binding to defined pockets on proteins, triggering their proteolysis.?? ? However, we recognize that even the most advanced small molecule #TPD approaches struggle with proteins that lack deep pockets. That is why we developed our Helicon degraders. With a 3-4x larger surface area, Helicon degraders can engage with highly challenging drivers of disease that small molecules cannot.? ? This unique capability allows us to pursue critical, yet historically “undruggable,” targets such as β-catenin, ERG, and a novel approach to AR. By expanding the boundaries of what can be targeted, we’re not just advancing technology – we’re paving the way for new therapeutic strategies that could redefine treatment paradigms. We’re advancing a pipeline of first-in-class Helicon degraders, including a degrader of ERG – a key driver of #ProstateCancer – expected to enter IND-enabling activities this year. Learn more at https://lnkd.in/eWzFMkt9 #ParabilisMedicines #CreatingExtraordinaryMedicines #Oncology #Helicons?

March is #CRCAwarenessMonth, an opportunity to shed light on the massive need for better screening, prevention, and treatment of #ColorectalCancer.??? ?? Activating mutations in the Wnt/β-catenin signaling pathway are found in 80-90% of colorectal cancer and are often associated with poor prognosis and resistance to treatment. To date, no approved therapies target this mechanism.??? ?? FOG-001, our lead investigational candidate, is the first and only direct inhibitor of β-catenin interactions with the TCF family of transcription factors. Now in a Phase 1/2 clinical trial, FOG-001 is designed to target the root cause of many colorectal cancers – pushing the boundaries of #drugdiscovery and development to bring innovative therapies to patients who need them.? ? Learn more about FOG-001: https://lnkd.in/eEJswkV2?? ? #ColorectalCancer #CancerResearch #Oncology #CRCSM?

Parabilis Profiles: Meet Paula Ortet, Ph.D., Senior Scientist at Parabilis. Paula is an expert in peptide chemistry with over a decade of experience designing and optimizing structurally-constrained peptides.? With deep expertise in peptide synthesis, characterization, and purification, Paula plays a key role in advancing Parabilis’s groundbreaking Helicon platform. Learn more about Paula and her journey toward #CreatingExtraordinaryMedicines.? #ParabilisMedicines #TeamParabilis #DrugDiscovery??

#BlackHistoryMonth is a time to reflect, learn, and celebrate the powerful stories of Black Americans that have shaped our collective history.? To recognize the month, we asked our team to share books and films that have deepened their understanding of Black history and culture. Here are some of their top recommendations: ?? “I Know Why the Caged Bird Sings” – Maya Angelou? ?? “Becoming” – Michelle Obama? ?? “The Immortal Life of Henrietta Lacks” – Rebecca Skloot? ?? “Born a Crime” – Trevor Noah? ?? “Children of Blood and Bone” – Tomi Adeyemi? ?? “Nickel Boys” – Colson Whitehead? ?? “Kindred” – Octavia Butler? ?? “Their Eyes Were Watching God” – Zora Neale Hurston? ?? “The Color Purple” – Alice Walker ?? “12 Years a Slave”? ?? “If Beale Street Could Talk”? ?? “Hidden Figures”? ?? “Double Victory: The Tuskegee Airmen at War”? ?? “Racist Trees” ? ?? “Summer of Soul (…Or, When the Revolution Could Not Be Televised)” #TeamParabilis #ParabilisMedicines??

Parabilis Chief Business Officer Gregory Miller joined the Labiotech.eu Beyond Biotech podcast recently to share reflections on the state of the biotech industry coming out of #JPM25 and into the year ahead.?? ? Greg shared his take on areas of emerging dealmaking interest, the funding environment for incremental vs. transformational innovations, and the transitional state the sector is now in.?? ? Listen here: https://lnkd.in/dhVv_FgD?? ? #BeyondBiotech #Biotech #BusinessDevelopment?

Today, on International Day of Women and Girls in Science, we celebrate the women in Research and Development at Parabilis who are driving our progress toward #CreatingExtraordinaryMedicines. Hear from some of the incredible women on our team about what inspires them to push the boundaries of what’s possible in science and medicine. #WomenInScience #WomenInSTEM #Biotech #DrugDiscovery?

When it comes to discovering therapies against new targets, we forge ahead where many others stop.? Many compelling targets aren’t amenable to small molecule or antibody drugs, and therefore are discarded without a second thought. That means that patients whose diseases may be driven by such biology will not benefit from a medicine.? ?At Parabilis we are able to engage these traditionally undruggable targets with our Helicon peptides — making it possible to turn once-inactionable therapeutic hypotheses into transformative medicines.? Learn more about our R&D focus: https://lnkd.in/eZQ-Fdp8? #ParabilisMedicines #DrugDiscovery #Oncology?

Today, on #WorldCancerDay, we are honored to be part of the drug development community that’s making inroads in the fight against cancer.? Still, with nearly 10 million lives lost annually to this devastating disease, our work to develop transformative medicines for traditionally undruggable targets is more critical than ever. This mission extends beyond our walls and touches many of us personally. Hear our Parabilis team members share what it means to them to be #CreatingExtraordinaryMedicines for cancer.? #CancerResearch #Oncology #BeatCancer #DrugDiscovery?

At this year’s Innovations in Regulatory Science Summit hosted by UCSF-Stanford CERSI (Center of Excellence in Regulatory Science and Innovation), Parabilis CEO Mathai Mammen, M.D., Ph.D., took the stage for an Oxford-style debate.?? ? Mathai and Donna Boyce of Pfizer engaged in a dynamic debate about FDA transparency surrounding sponsor-level decisions, with former FDA Commissioner Mark McClellan moderating.? ? Taking the position in favor of increased transparency, Mathai emphasized how openness can drive innovation, enhance trust in regulatory processes, and benefit patients.?? ? Watch the full debate here: https://lnkd.in/e5GUnFnt?? ? #CERSI #JPM25 #RegulatoryScience?